Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

BioLineRx Ltd. Logo
Biopharma firm developing and commercializing therapies for cancer and rare diseases.
Israel
BLRX
BIOMARIN PHARMACEUTICAL INC Logo
Develops and commercializes therapies for rare, life-threatening genetic diseases.
United States of America
BMRN
BioMaxima S.A. Logo
Manufacturer of IVD solutions including tests, reagents, and equipment for medical labs.
Poland
BMX
Biomea Fusion, Inc. Logo
Develops oral small molecules for metabolic diseases like diabetes and for specific cancers.
United States of America
BMEA
BIOMERICA INC Logo
Develops diagnostic tests for GI, inflammatory diseases, and diabetes for lab and at-home use.
United States of America
BMRA
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France
BIM
BiomX Inc. Logo
Develops phage therapies to target harmful bacteria in chronic diseases like cystic fibrosis.
United States of America
PHGE
BIONEERCORPORATION Logo
Provides molecular biology tools & diagnostic kits for research and clinical applications.
South Korea
064550
BioNTech SE Logo
Pioneering mRNA immunotherapies and vaccines to combat cancer and infectious diseases.
United States of America
BNTX
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark
BIOPOR

Talk to a Data Expert

Have a question? We'll get back to you promptly.